BMO Expands Canadian Depositary Receipt Lineup with 10 New Listings from Europe and Japan

BMO's CDRs offer enhanced portfolio diversification opportunities for Canadian investors enabling them to hold shares in international companies that trade on a Canadian exchange in Canadian dollars

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

BMO's new CDRs will trade under the following tickers:

Company Name

CDR Ticker

Jurisdiction

Novo Nordisk A/S

NOVE

Denmark

SAP SE

SAPG

Germany

ASML Holding NV

ASMH

Netherlands

CIE Financiere Richemont AG

RCHM

Switzerland

Novartis AG

NOVN

Switzerland

Roche Holdings AG

ROCH

Switzerland

UBS Group AG

UBS

Switzerland

Mitsubishi Corp.

MTSU

Japan

Mitsubishi UFJ Financial Group

MUFG

Japan

Softbank Group Corp.

SFTB

Japan

For more information on BMO's CDRs, please visit www.bmocdrs.com .

This material is for information purposes only. The information contained herein is not, and should not be construed as, investment, tax or legal advice to any party.

An investment in CDRs issued by BMO may not be suitable for all investors. Important information about these investment products is contained in the short form base shelf prospectus and prospectus supplement for each series of CDRs (together, the " Prospectus "). Purchasers are directed to www.sedarplus.ca or to www.bmogam.com to obtain copies of the Prospectus and related disclosure before purchasing CDRs of a particular series. The information contained herein is not a recommendation to purchase these investment products.

Each series of CDRs relates to a single class of equity securities (the " Underlying Shares ") of an issuer incorporated outside of Canada (the " Underlying Issuer "). For each series of CDRs, the Prospectus will provide additional information regarding such series, including information regarding the Underlying Issuer and Underlying Shares for such series. Neither BMO and its affiliates nor any other person involved in the distribution of CDRs accepts any responsibility for any disclosure provided by any Underlying Issuer (including information contained herein or in the Prospectus that has been extracted from any Underlying Issuer's publicly disseminated disclosure). Each series of CDRs is only offered to investors in Canada in accordance with applicable laws and regulatory requirements.

"BMO (M-bar roundel symbol)" is a registered trademark of Bank of Montreal , used under licence.

About BMO Financial Group

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.41 trillion as of October 31, 2024. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States , and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life , BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.

SOURCE BMO Financial Group

News Provided by PR Newswire via QuoteMedia

NVS
The Conversation (0)
Red Mountain Mining

Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter

Red Mountain Mining Limited (ASX: RMX, US CODE: RMXFF, or “Company”), a Critical Minerals exploration and development company with an established portfolio in Tier-1 Mining Districts in the United States and Australia, is pleased to announce the Company’s newly-acquired Thompson Falls Antimony... Keep Reading...
Lahontan Drills More Shallow Oxide Gold at Slab: 69m Grading 0.45 g/t Au Eq Including 17m Grading 0.81 g/t Au Eq

Lahontan Drills More Shallow Oxide Gold at Slab: 69m Grading 0.45 g/t Au Eq Including 17m Grading 0.81 g/t Au Eq

TORONTO, ON / ACCESS Newswire / January 27, 2026 / Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF)(OTCQB:LGCXF)(FSE:Y2F) (the "Company" or "Lahontan") is pleased to announce new assay results from our 2025 Phase Two drilling program at the Company's flagship Santa Fe Mine Project located in Nevada's... Keep Reading...
Nextech3D.ai's KraftyLab Accelerates Global Scale with Launch of In-Person Experiences and AI-Driven Platform Automation

Nextech3D.ai's KraftyLab Accelerates Global Scale with Launch of In-Person Experiences and AI-Driven Platform Automation

Expanded our physical footprint to 20 major cities and integrated 50%+ new experiences. TORONTO, ON AND NEW YORK, NY / ACCESS Newswire / January 14, 2026 / Nextech3D.ai (CSE:NTAR,OTC:NEXCF)(OTCQB:NEXCF)(FSE:1SS), an AI-first technology company specializing in AI-powered live event solutions, 3D... Keep Reading...
Raptor Resources

Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada

Eastern Metals Ltd (ASX: EMS) (Eastern Metals or the Company) (to be renamed Raptor Metals Ltd (ASX: RAP)) is pleased to advise it has recommenced trading on the Australian Securities Exchange (ASX) today following its acquisition of Raptor Resources Limited (Raptor Resources). HIGHLIGHTS... Keep Reading...
Lahontan Drills Thick, Shallow Gold: 114m Grading 0.33 g/t Au Eq at York; 23m Grading 0.42 g/t Au Eq at Slab

Lahontan Drills Thick, Shallow Gold: 114m Grading 0.33 g/t Au Eq at York; 23m Grading 0.42 g/t Au Eq at Slab

TORONTO, ON / ACCESS Newswire / January 13, 2026 / Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF)(OTCQB:LGCXF) (the "Company" or "Lahontan") is pleased to announce the first results from our 2025 Phase Two drilling program at the Company's flagship Santa Fe Mine Project located in Nevada's prolific... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
Pill labeled "GLP-1" on a $100 bill background.

As GLP-1 Brands Go Prime Time, Regulators Flag Growing Illicit Market

At Super Bowl LX, companies behind blockbuster GLP-1 medications spent tens of millions of dollars to court a mass audience. But as brand-name makers and telehealth platforms race to normalize and expand access, regulators on both sides are warning of a parallel surge in counterfeit, compounded,... Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...

Interactive Chart

Latest Press Releases

Related News